Regulation of drug-metabolizing enzymes by sex-related hormones: clinical implications for transgender medicine

Regulation of drug-„metabolizing enzymes by sex-„related hormones: clinical implications for transgender medicine
Transgender people represent a diverse and growing population
Testosterone and estrogen treatment are associated with increased quality of life among transgender adults
Transgender people may undergo testosterone or estrogen treatment
Investigators have not yet established the effect of testosterone or estrogen treatment on drug-metabolizing enzyme activit...
CYP3A metabolizes several medication classes prescribed for transgender people, including anti-HIV agents, such as protease...
CYP2B6 metabolizes several therapeutically used drugs prescribed for transgender adults, including the anti-HIV agent efavirenz
CYP2C9 and 2C19 metabolize several important medications prescribed for transgender adults, including warfarin and clopidog...
CYP2D6 metabolizes several psychotropic medications that may be prescribed for transgender adults
CYP2E1 metabolizes medications taken by transgender people, including acetaminophen
CYP1A2 metabolizes certain psychotropic medications that may be prescribed for transgender adults
UGT metabolizes several medications prescribed for transgender adults, including lamotrigine
Sex steroid-related activation of drug transporter protein expression or activity among transgender adults is not established
Endogenous hormones may indirectly influence drug-metabolizing enzyme activity in transgender adults
Adjunctive agents modify the extent of potential effects of estrogen treatment on drug-metabolizing enzymes for transgender...
Nonhormonal sex-related and gender-related factors may also influence drug safety for transgender people
Concluding remarks and future perspectives
Declaration of interests
Resources
References